PXS Share Purchase Plan

pxs hero 7

Pharmaxis Ltd (ASX: PXS) is pleased to announce it has launched a Share Purchase Plan (SPP) to strengthen the Pharmaxis balance sheet as the Company conducts two clinical studies of its lead drug PXS-5505 in cancer. The SPP gives Eligible Shareholders the opportunity to acquire up to $30,000 of new fully paid ordinary shares in Pharmaxis (SPP Shares), at an Issue Price of $0.105 per SPP Share without incurring brokerage or transaction costs.


SPP Key Highlights

  • Price – Shares are offered under the SPP at an Issue Price of $0.105 per SPP Share, which represents:
    • a 12.4% discount to the volume weighted average price of $0.1198 on Friday, 12 November 2021; and
    • a 12.0% discount to the volume weighted average price of Pharmaxis Shares traded on the ASX over the last five days on which sales in Pharmaxis Shares were recorded before Wednesday, 17 November 2021 (being the date on which the SPP was announced).
  • Eligible Shareholders – Participation in the SPP is optional and is open to Eligible Shareholders, including Eligible Shareholders who are Custodians on behalf of Eligible Beneficiaries on the term and conditions set out in this Offer Booklet. Your right to participate in the SPP is not transferable.
  • Offer Period – The SPP opens on Thursday, 25 November 2021, and is expected to close at 5:00pm (Sydney, Australia time) on Wednesday, 15 December 2021.
  • Ranking of SPP Shares – All SPP Shares issued under the SPP will rank equally with existing Pharmaxis Shares after commencement of trading.

In addition to the SPP, on Wednesday, 17 November 2021, Pharmaxis announced that it had raised ~$7.2 million by way of a Placement of new fully paid ordinary shares to institutional and professional investors (Placement).  Pharmaxis also announced that it intended to raise approximately $2 million by way of an offer to Eligible Shareholders under an SPP.

The funds raised will be used to strengthen the Pharmaxis balance sheet as the Company conducts two clinical studies of its lead drug PXS-5505 in cancer - a phase 2a study in myelofibrosis is already recruiting and a phase 1c/2a investigator led study in liver cancer (Hepatocellular Carcinoma or HCC) being conducted with the University of Rochester is expected to commence in the first half of 2022. A study of Pharmaxis topical drug PXS-6302 in patients with wound and burns scarring is expected to commence dosing in patients later this quarter.


Record Date for SPP

Tue, 16 Nov 2021

Despatch of SPP Offer Booklet 

Thurs, 25 Nov  2021

SPP Opening Date 

Thurs, 25 Nov 2021

SPP Closing Date

Wed, 15 Dec 2021 

Announcement of SPP Results 

Mon, 20 Dec 2021 

Allotment and Trading of SPP Shares 

Wed, 22 Dec  2021 

Pharmaxis Live Investor Briefing

Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips on Wednesday 8th December 2021.

The event will consist of a short presentation of the Company’s recent progress and future plans post capital raising followed by a Q&A session from attendees.

Session Time:
Wednesday 8th December at 10:30am AEDT
Click here to register for the Investor Briefing 

Recent Interview with Pharmaxis CEO Gary Phillips

Recent Announcements

Click here to view all ASX announcements


Contact Information

If you have any questions in relation to how to participate in the SPP, please contact the Pharmaxis by email at david.mcgarvey@pharmaxis.com.au

Important Notice and Disclaimer

This webpage contains important information. If you are an Eligible Shareholder, this document requires your immediate attention, and should be read in its entirety. 

This webpage does not provide financial advice and has been prepared without taking account of any person’s investment objectives, financial situation or particular needs. You should consider the appropriateness of participating in the SPP having regard to your investment objectives, financial situation and particular needs. You should consult your stockbroker, solicitor, accountant or other professional adviser before making any investment decision in relation to this Offer.

The offer of SPP Shares under the SPP is made in accordance with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (ASIC Instrument) which grants relief from the requirement for Pharmaxis to prepare a disclosure document for the SPP subject to certain terms and conditions. This webpage is not a prospectus under the Corporations Act and has not been lodged with ASIC.

Overseas Shareholders

The laws of some countries prohibit or make impractical, participation in the SPP by certain overseas Shareholders. Shareholders who are not resident in Australia or New Zealand will not be able to participate in the SPP. The SPP does not constitute an offer of Pharmaxis Shares for sale in any other jurisdiction.

New Zealand

The SPP Shares are not being offered or sold to the public within New Zealand other than to existing Shareholders of Pharmaxis at the Record Date shown on the Register to have registered addresses in New Zealand to whom the offer of SPP Shares is being made in reliance on the Financial Markets Conduct (Incidental Offers) Exemption Notice 2016.

This webpage has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013. This webpage is not a product disclosure statement under New Zealand law and is not required to, and may not, contain all the information that a product disclosure statement under New Zealand law is required to contain.

Application payments must be received in Australian dollars.

United States

This webpage does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any place outside Australia or New Zealand. In particular, this webpage does not constitute an offer to sell, or a solicitation of an offer to buy, any Shares in the United States or to any person acting for the account or benefit of any person in the United States. The SPP Shares have not been and will not be registered under the US Securities Act of 1933 (as amended) (Securities Act). The SPP Shares may not be offered, sold or otherwise transferred in the United States except in a transaction exempt from, or not subject to, the registration requirements of the Securities Act and the applicable securities laws.